调研速递|三诺生物接受多家机构调研 聚焦业务布局与市值管理要点

Core Viewpoint - The company participated in an online investor reception event, discussing its product offerings, stock management, digital transformation, and market conditions, particularly focusing on diabetes management products and strategies for growth in both domestic and international markets [1] Group 1: Investor Relations Activity - The investor relations activity was held on September 19, 2025, from 15:40 to 17:00 via the "Panorama Roadshow" website [1] - Key participants included the Deputy General Manager and Board Secretary, Zheng Jiyun, and Securities Affairs Representative, Xu Huiyu [1] Group 2: Product Layout - The company primarily focuses on diabetes and related chronic disease detection products, with its subsidiary Trividia Health, Inc. offering the "TRUE" series of blood glucose monitoring products and diabetes care items [1] Group 3: Stock Price and Market Management - In response to concerns about stock price declines during a bull market, the company confirmed normal operations and disclosed no undisclosed matters [1] - The company has initiated a "Quality and Return Dual Improvement" action plan since 2024 and has repurchased 4,824,900 shares for a total amount of approximately 99.92 million yuan as of August 31, 2025 [1] Group 4: Digital Transformation and Business Outlook - The company is enhancing its diabetes management ecosystem by deploying IoT technology and launching a smart diabetes management system [1] - The "Aikan Health" app is set to launch in the HarmonyOS NEXT application market in September 2024, with plans for further digital transformation and AI integration [1] Group 5: Tariff Impact - In the first half of 2025, the company reported revenue of approximately 226.37 million yuan, with 32.86% coming from the U.S. market [1] - The company noted that most U.S. revenue is generated from local production, thus not affected by "reciprocal tariffs," and has sufficient inventory to mitigate tariff impacts [1] Group 6: CGM Business - The company plans to refine its second and third-generation Continuous Glucose Monitoring (CGM) products based on FDA feedback and expedite new product IDE applications [1] - The company views domestic price competition as a natural phase of market development, with a focus on sustainable long-term growth despite short-term profitability impacts [1]